Calithera Biosciences (NASDAQ:CALA) released its quarterly earnings results on Wednesday. The biotechnology company reported ($0.52) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.12), Fidelity Earnings reports. Calithera Biosciences had a negative net margin of 90.65% and a negative return on equity of 22.09%.
Calithera Biosciences stock opened at $4.90 on Friday. Calithera Biosciences has a 52 week low of $4.05 and a 52 week high of $16.50. The company has a market cap of $181.02 million, a price-to-earnings ratio of -5.83 and a beta of 2.35.
Several research firms have commented on CALA. ValuEngine raised shares of Calithera Biosciences from a “hold” rating to a “buy” rating in a research report on Thursday, November 1st. Zacks Investment Research cut shares of Calithera Biosciences from a “buy” rating to a “hold” rating in a research report on Wednesday, October 24th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the stock. Calithera Biosciences currently has a consensus rating of “Hold” and an average target price of $9.88.
Calithera Biosciences Company Profile
Calithera Biosciences, Inc, a clinical-stage bio-pharmaceutical company, focuses on the discovery and development of small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. Its lead product candidate is CB-839, an inhibitor of glutaminase, which is in Phase II clinical trial to treat solid tumors.
Featured Article: Yield Curve
Receive News & Ratings for Calithera Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calithera Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.